Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
Completed · Phase 2 · Has a placebo group
Conditions studied: West Nile Fever
In brief
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease. The study is divided into two parts; in the first part, a comparison of 3 dose levels of the vaccine will be made, with an inactive control. In the second part, the optimum dose level chosen after the first part will be given to older volunteers.
Key facts
- Study ID
- NCT00442169
- Run by
- Sanofi Pasteur, a Sanofi Company
- People needed
- 208
- Starts
- 2005-12-01
- Expected to finish
- 2009-04-01
- Last updated by the study team
- 2016-04-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- HOPE Research Institute — Phoenix, Arizona, United States
- Idaho Infectious Diseases, PLLC — Idaho Falls, Idaho, United States
- PRA International Clinical Pharmacology Center — Lenexa, Kansas, United States
- Bio-Kinetic Clinical Applications, Inc. — Springfield, Missouri, United States
- The Glennan Centre for Geriatrics and Gerontologyy, EVMS — Norfolk, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.